325 related articles for article (PubMed ID: 31396668)
1. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Ahlawat S; Blakeley JO; Langmead S; Belzberg AJ; Fayad LM
Skeletal Radiol; 2020 Feb; 49(2):199-219. PubMed ID: 31396668
[TBL] [Abstract][Full Text] [Related]
2. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
[TBL] [Abstract][Full Text] [Related]
3. Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis.
Thomas AK; Egelhoff JC; Curran JG; Thomas B
Pediatr Radiol; 2016 Mar; 46(3):430-5. PubMed ID: 26546566
[TBL] [Abstract][Full Text] [Related]
4. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Plotkin SR
Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
[TBL] [Abstract][Full Text] [Related]
6. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
[TBL] [Abstract][Full Text] [Related]
7. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.
Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Schneider KW; Scott HS; Plon SE; Tabori U
Clin Cancer Res; 2017 Jun; 23(12):e46-e53. PubMed ID: 28620004
[TBL] [Abstract][Full Text] [Related]
8. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
[TBL] [Abstract][Full Text] [Related]
9. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.
Ahlawat S; Baig A; Blakeley JO; Jacobs MA; Fayad LM
J Magn Reson Imaging; 2016 Oct; 44(4):794-803. PubMed ID: 26991037
[TBL] [Abstract][Full Text] [Related]
11. Dorsal root ganglia volume differentiates schwannomatosis and neurofibromatosis 2.
Godel T; Mautner VF; Farschtschi S; Pham M; Schwarz D; Kronlage M; Gugel I; Heiland S; Bendszus M; Bäumer P
Ann Neurol; 2018 Apr; 83(4):854-857. PubMed ID: 29469988
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
Banerjee J; Friedman JM; Klesse LJ; Yohay KH; Jordan JT; Plotkin SR; Allaway RJ; Blakeley JO
Genet Med; 2023 Feb; 25(2):100324. PubMed ID: 36565307
[TBL] [Abstract][Full Text] [Related]
13. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
[TBL] [Abstract][Full Text] [Related]
14. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
[TBL] [Abstract][Full Text] [Related]
15. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Plotkin SR; Messiaen L; Legius E; Pancza P; Avery RA; Blakeley JO; Babovic-Vuksanovic D; Ferner R; Fisher MJ; Friedman JM; Giovannini M; Gutmann DH; Hanemann CO; Kalamarides M; Kehrer-Sawatzki H; Korf BR; Mautner VF; MacCollin M; Papi L; Rauen KA; Riccardi V; Schorry E; Smith MJ; Stemmer-Rachamimov A; Stevenson DA; Ullrich NJ; Viskochil D; Wimmer K; Yohay K; ; Huson SM; Wolkenstein P; Evans DG
Genet Med; 2022 Sep; 24(9):1967-1977. PubMed ID: 35674741
[TBL] [Abstract][Full Text] [Related]
16. Whole body MRI with DWI in people with NF1 and Schwannomatosis: Are qualitative and quantitative imaging features of peripheral lesions comparable to localized MRI?
Debs P; Fayad LM; Romo CG; Ahlawat S
Eur J Radiol; 2023 May; 162():110802. PubMed ID: 37001256
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
18. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
19. [Seizures in neurofibromatosis. What is the risk?].
Drouet A
Rev Neurol (Paris); 2011 Dec; 167(12):886-96. PubMed ID: 22041820
[TBL] [Abstract][Full Text] [Related]
20. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
